©2009 Baishideng. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2009; 1(1): 62-68
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.62
Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer
Farha A El-Chennawi, Fatma A Auf, Shereen S Metwally, Youssef M Mosaad, Ziyad E Tawhid, Zakaria F Lotfy, Clinical Immunology Unit, Clinical Pathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura 35111, Egypt
Atallah A Shaaban, Urology & Nephrology Center, Mansoura Faculty of Medicine, Mansoura University, Mansoura 35111, Egypt
Mahmoud Abdo El-Baz, Pathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura 35111, Egypt
Author contributions: El-Chennawi FA, Shaaban AA, and Auf FA contributed equally to this work; Metwally SS designed the research; Lotfy ZF performed the research; Tawhid ZE contributed new reagents/analytic tools; El-Baz MA performed the pathological part of the research; Mosaad YM wrote the paper.
Supported by A grant from the research unit, Mansoura University
Correspondence to: Dr. Youssef M Mosaad, Professor, Clinical Immunology Unit, Clinical Pathology Department, Mansoura Faculty of Medicine, Mansoura 35111, Egypt. firstname.lastname@example.org
Telephone: +20-50-2247042 Fax: +20-50-2267563
Received: July 2, 2009
Revised: August 16, 2009
Accepted: August 23, 2009
Published online: October 15, 2009
AIM: To evaluate the relationship between vascular endothelial growth factor (VEGF), p53, and the H-ras oncogene and different clinicopathological parameters in Egyptian patients with Schistosoma-associated transitional cell carcinoma of the bladder.
METHODS: The study included 50 patients with transitional cell carcinoma for whom radical cystectomy and urinary diversions were carried out. VEGF and p53 protein expressions were evaluated with an immunohistochemical staining method, and H-ras oncogene mutations were analyzed with a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.
RESULTS: High grade tumors revealed higher p53 immunostaining than low grade tumors (P = 0.016). p53 and VEGF protein expressions, as well as H-ras oncogene mutations, had an insignificant impact on patient outcomes (P = 0.962, P = 0.791, and P = 967, respectively). Cancer extension to regional lymph nodes was associated with poor outcomes (P = 0.008).
CONCLUSION: VEGF, p53 and the H-ras oncogene have no relation to patient survival and outcome in Schistosoma-associated transitional cell carcinoma.